

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE


Single Technology Appraisal

Vutrisiran for treating transthyretin-related amyloidosis cardiomyopathy [ID6470]

Final Stakeholder List

Provisional Consultees	Provisional Commentators (no right to submit or appeal)
Company	General
Alnylam Pharmaceuticals (vutrisiran)	All Wales Inherited Metabolic Disease Service
Patient/carer groups • Amyloidosis UK	All Wales Therapeutics and Toxicology Centre
Arrythmia Alliance	Allied Health Professionals Federation
Atrial Fibrillation Association	Association of Renal Industries
British Liver Trust	Board of Community Health Councils in
Cardiomyopathy UK	Wales
Cardiovascular Care Partnership	British National Formulary
Circulation Foundation	Care Quality Commission
Gene People	Cell and Gene Therapy Catapult
Genetic Alliance UK	Department of Health - Northern Ireland
HEART UK	Healthcare Improvement Scotland
Liver4Life	Medicines and Healthcare products
Pumping Marvellous	Regulatory Agency
Somerville Foundation	National Association of Primary Care
South Asian Health Foundation	National Pharmacy Association
Specialised Healthcare Alliance	National Services Division
	NHS Confederation
Healthcare professional groups	Scottish Medicines Consortium
Association of Genetic Nurses and	Welsh Government
Counsellors	Welsh Health Specialised Services
British Cardiovascular Society British Cardiovascular Society	Committee
British Geriatrics Society British Nuclear Cardialagus Society	Comparator companies
British Nuclear Cardiology Society British Society of Cabacardiagraphy	Pfizer (tafamidis)
British Society of Echocardiography British Society for Gone and Coll	Tile (talallius)
British Society for Gene and Cell Therapy	Relevant research groups
British Society for Genetic Medicine	Cochrane Heart Group
Haemochromatosis UK	Genomics England
National Heart and Lung Institute	MRC Clinical Trials Unit
Primary Care Cardiovascular Society	National Centre for Cardiovascular
 Royal College of General Practitioners 	Preventions and Outcomes
Royal College of Nursing	National Institute for Health Research

Final stakeholder list for the evaluation of vutrisiran for treating transthyretin-related amyloidosis cardiomyopathy [ID6470]



Provisional Consultees	Provisional Commentators (no right to submit or appeal)
 Royal College of Pathologists Royal College of Physicians Royal Pharmaceutical Society Royal Society of Medicine UK Clinical Pharmacy Association Vascular Society of Great Britain and Ireland 	Associated Public Health groups Public Health Wales UK Health Security Agency
OthersDepartment of Health and Social CareNHS England	

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).


All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations

Final stakeholder list for the evaluation of vutrisiran for treating transthyretin-related amyloidosis cardiomyopathy [ID6470]

Issue date: November 2024



and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.